2550 Stanwell Drive
384 articles with Cerus Corporation
Cerus Corporation today announced the appointment of Eric Bjerkholt to its Board of Directors.
Institutional Investor Meeting on Tuesday, October 16, 2018 in Boston, Massachusetts.
Cerus’ president and chief executive officer will present and provide a corporate update at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York City on Tuesday, October 2, 2018 at 3:25 p.m. ET.
Product revenue increases 62% compared to 2017
Cerus Corporation announced today that its second quarter results will be released on Thursday, August 2, 2018, after the close of the stock market.
Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association
Cerus Corporation announced that results from SPARC were presented today at the 23rd Congress of European Hematology Association.
Cerus Announces Presentations Highlighting INTERCEPT Blood Systems at the 35th International Congress of the International Society of Blood Transfusion
Cerus Corporation announced that it will make multiple presentations, including two oral abstracts, that will be featured at the 35th International Congress of the International Society of Blood Transfusion (ISBT).
Cerus Corporation announced that Dr. Laurence M. Corash, co-founder and chief scientific officer, and Lainie Corten, vice president of global marketing, are scheduled to present a corporate update at the Deutsche Bank 43rd Annual Health Care Conference.
RedeS is a Phase 3 study designed to evaluate the safety and efficacy of INTERCEPT Blood Systems for Red Blood Cells (RBCs) compared to conventional RBCs in regions impacted by the Zika virus.
Cerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center Customer
Received approval from the FDA for allowance of interstate distribution of platelets that have been pathogen-reduced with the INTERCEPT Blood System.
Cerus Corporation announced financial results for the fourth quarter and year ended December 31, 2017.
Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
Cerus today announced the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares.
Cerus announced that it has commenced a registered underwritten public offering of $50.0 million of its common stock.
Cerus Corporation today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $50.0 million, before deducting estimated offering expenses payable by Cerus.
Cerus Reports Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells in Thalassemia Patients
The results from the SPARC study provide important clinical data regarding the safety profile of INTERCEPT-treated RBCs in a chronically transfused patient population and support Cerus’ INTERCEPT RBC CE mark submission, which is planned for the second half of 2018.
Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017
Cerus’ unaudited preliminary product revenue for the fourth quarter of 2017 was $16.2 million, an increase of 60% compared to fourth quarter of 2016.
ReCePI is designed to evaluate the efficacy and safety of INTERCEPT Red Blood Cells (RBCs) in patients requiring transfusion for acute blood loss during surgery.
At September 30, 2017, the Company had cash, cash equivalents and short-term investments of $59.6 million compared to $71.6 million at December 31, 2016.
Cerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System Portfolio in Italy
Kedrion Biopharma will initially distribute INTERCEPT for platelets and plasma and will have the right to distribute INTERCEPT red blood cells following CE mark approval.
Cerus Corporation announced today that the Institute for the Hospital Remuneration System (Institut für das Entgeltsystem im Krankenhaus, or InEK) in Germany will include pathogen-inactivated platelets for national reimbursement starting January 1, 2018.